Obsidian Therapeutics, Inc.

S-1 filed

29,164,045 shares · Gross proceeds $0.00

CERT inactive

8-A12B effective

EFFECT effective

424B3 priced

Gross proceeds $350,000,000

Gazelle Parent, Inc. has filed a 424B3 registration statement related to a merger involving Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. The filing outlines legal provisions for dispute resolution, including exclusive forum selections for securities-related claims and derivative actions. It references the involvement of Sidley as legal counsel and KPMG LLP as auditors. The document includes consolidated financial statements for both Galera and Obsidian, with KPMG noting substantial doubt about Obsidian's ability to continue as a going concern due to recurring losses and negative cash flow.

S-4/A amended

Gross proceeds $350,000,000

S-4/A amended

Gross proceeds $350,000,000

S-4/A amended

S-4/A amended

S-4 filed

Gazelle Parent, Inc. filed an S-4 registration statement for a proposed merger involving Galera Therapeutics, Inc., Obsidian Therapeutics, Inc., and related entities. The filing outlines the merger of Merger Sub 1 with Obsidian and Merger Sub 2 with Galera, resulting in a combined company. The transaction includes the conversion of preferred stock and warrants into common stock, a concurrent $350 million financing, and contingent value rights (CVRs) for Galera shareholders. Parent will rename itself Obsidian Therapeutics post-merger. No public market exists for Parent's stock, and the SEC has not approved the transaction.